Pathogen recognition and innate immunity, Cell, vol.124, pp.783-801, 2006. ,
Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev, vol.220, pp.225-236, 2007. ,
Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease, Immunol Rev, vol.204, pp.27-42, 2005. ,
Modulating vaccine responses with dendritic cells and Toll-like receptors, Immunol Rev, vol.199, pp.227-250, 2004. ,
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer, Oncogene, vol.27, pp.161-167, 2008. ,
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides, J Immunol, vol.168, pp.4531-4537, 2002. ,
A role for Toll-like receptors in acquired immunity: upregulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells, Blood, vol.101, pp.4500-4504, 2003. ,
The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells, Blood, vol.102, pp.956-963, 2003. ,
Toll-like receptors in systemic autoimmune disease, Nat Rev Immunol, vol.6, pp.823-835, 2006. ,
Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32), Virology, vol.278, pp.86-94, 2000. ,
Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity, Immunol Rev, vol.220, pp.251-269, 2007. ,
A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation, Immunology, vol.118, pp.539-548, 2006. ,
Toll-like receptor 2-mediated human B cell differentiation, Clin Immunol, vol.120, pp.272-284, 2006. ,
Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines, J Immunol, vol.168, pp.554-561, 2002. ,
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN, J Immunol, vol.174, pp.4043-4050, 2005. ,
TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses, J Immunol, vol.178, pp.7779-7786, 2007. ,
Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets, PLoS ONE, vol.2, p.863, 2007. ,
, Cell Death Differ, vol.13, pp.816-825, 2006.
TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation, Eur J Immunol, vol.38, pp.400-409, 2008. ,
Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105, J Leukoc Biol, vol.82, pp.265-271, 2007. ,
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides, Clin Cancer Res, vol.11, pp.1490-1499, 2005. ,
Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells, Leukemia, vol.20, pp.286-295, 2006. ,
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease, Leukemia, vol.21, pp.110-120, 2007. ,
Tolllike receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents, Cancer Res, vol.67, pp.1823-1831, 2007. ,
Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod, Leuk Lymphoma, vol.46, pp.935-939, 2005. ,
Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors, Leukemia, vol.20, pp.1130-1137, 2006. ,
Tolllike receptors mediate proliferation and survival of multiple myeloma cells, Leukemia, vol.20, pp.1138-1144, 2006. ,
The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2028, 2006. ,
Staphylococcus aureus protein A triggers T cellindependent B cell proliferation by sensitizing B cells for TLR2 ligands, J Immunol, vol.178, pp.2803-2812, 2007. ,
Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing, J Exp Med, vol.186, pp.931-940, 1997. ,
TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function, Eur J Immunol, vol.37, pp.2205-2213, 2007. ,
Toll-like receptor stimulation as a third signal required for activation of human naive B cells, Eur J Immunol, vol.36, pp.810-816, 2006. ,
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6, Immunity, vol.19, pp.225-234, 2003. ,
Dendritic cells control B cell growth and differentiation, Curr Dir Autoimmun, vol.8, pp.124-139, 2005. ,
Control of B-cell responses by Toll-like receptors, Nature, vol.438, pp.364-368, 2005. ,
Adjuvantenhanced antibody responses in the absence of toll-like receptor signaling, Science, vol.314, pp.1936-1938, 2006. ,
B cell intrinsic TLR signals amplify but are not required for humoral immunity, J Exp Med, vol.204, pp.3095-3101, 2007. ,
Immunology: Toll-like receptors and antibody responses, Nature, vol.441, p.4, 2006. ,
CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10, J Immunol, vol.173, pp.4479-4491, 2004. ,
Class switch recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptors, Immunity, vol.27, pp.64-75, 2007. ,
Tindependent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells, J Immunol, vol.178, pp.3593-3601, 2007. ,
Maintenance of serological memory by polyclonal activation of human memory B cells, Science, vol.298, pp.2199-2202, 2002. ,
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response, Blood, vol.105, pp.1614-1621, 2005. ,
Fcgamma-RIIb controls bone marrow plasma cell persistence and apoptosis, Nat Immunol, vol.8, pp.419-429, 2007. ,
MyD88 is required for the formation of long-term humoral immunity to virus infection, J Immunol, vol.178, pp.5124-5131, 2007. ,
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype, Exp Hematol, vol.28, pp.558-568, 2000. ,
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens, J Leukoc Biol, vol.69, pp.81-88, 2001. ,
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells, Blood, vol.95, pp.999-1006, 2000. ,
Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle, Blood, vol.84, pp.3457-3464, 1994. ,
Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity, J Immunol, vol.176, pp.3830-3839, 2006. ,
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN, J Leukoc Biol, vol.72, pp.83-92, 2002. ,
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells, J Leukoc Biol, vol.77, pp.378-387, 2005. ,
CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response, Blood, vol.105, pp.3641-3647, 2005. ,
Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia, Br J Haematol, vol.132, pp.452-458, 2006. ,
Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens, Clin Immunol Immunopathol, vol.75, pp.26-32, 1995. ,
Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat Rev Cancer, vol.5, pp.263-274, 2005. ,
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway, Blood, vol.110, pp.296-304, 2007. ,
Tolerance, not immunity, crucially depends on IL-2, Nat Rev Immunol, vol.4, pp.665-674, 2004. ,
IL-2 administration increases CD4? CD25(hi) Foxp3? regulatory T cells in cancer patients, Blood, vol.107, pp.2409-2414, 2006. ,
Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells, Leuk Lymphoma, vol.33, pp.147-153, 1999. ,
Endogenous ligands of Toll-like receptors, J Leukoc Biol, vol.76, pp.514-519, 2004. ,
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat Med, vol.13, pp.1050-1059, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00316924
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE, Nat Immunol, vol.8, pp.487-496, 2007. ,
TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity, Immunobiology, vol.213, pp.205-224, 2008. ,
Heparan sulfate proteoglycans and heparanasepartners in osteolytic tumor growth and metastasis, Matrix Biol, vol.23, pp.341-352, 2004. ,
Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective, Cancer Res, vol.66, pp.10233-10237, 2006. ,
HMGB1 expression and release by bone cells, J Cell Physiol, vol.207, pp.480-490, 2006. ,
Intratumoral CD4?CD25? regulatory T-cell-mediated suppression of infiltrating CD4? T cells in B-cell non-Hodgkin lymphoma, Blood, vol.107, pp.3639-3646, 2006. ,
Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells, Mol Ther, vol.16, pp.269-279, 2008. ,
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokinematured DCs in myeloma patients, Blood, vol.108, pp.2655-2661, 2006. ,
Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells, Blood, vol.108, pp.4071-4077, 2006. ,
Toll-like receptor 8-mediated reversal of CD4? regulatory T cell function, Science, vol.309, pp.1380-1384, 2005. ,
Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide, J Exp Med, vol.197, pp.403-411, 2003. ,
Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4? T cells that suppress the CD8? T cell response, J Immunol, vol.178, pp.5429-5433, 2007. ,
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics, J Immunol, vol.180, pp.3797-3806, 2008. ,
Distinct and overlapping roles of interleukin-10 and CD25? regulatory T cells in the inhibition of antitumor CD8 T-cell responses, Cancer Res, vol.65, pp.8479-8486, 2005. ,
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity, J Exp Med, vol.203, pp.413-424, 2006. ,
Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia, Haematologica, vol.91, pp.1697-1700, 2006. ,
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia, Blood, vol.109, pp.2198-2201, 2007. ,
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia, Leukemia, vol.21, pp.53-60, 2007. ,